Table 1

Demographics and baseline characteristics of patients with moderate to severe SLE who participated in the TULIP-1 or TULIP-2 trials and had available transcriptomics or proteomics data

Transcriptomic datasetProteomic dataset*
Anifrolumab 300 mgPlaceboAnifrolumab 300 mgPlacebo
Patientsn244258124132
Age, yearsMedian (range)44.0 (18–69)42.5 (18–68)40.0 (18–68)42.0 (18–68)
Sex, n (%)Female224 (91.8)239 (92.6)113 (91.1)124 (93.9)
Male20 (8.2)19 (7.4)11 (8.9)8 (6.1)
Race, n (%)†American Indian/Alaska Native4 (1.7)1 (0.4)00
Asian12 (5.0)16 (6.3)8 (6.5)4 (3.0)
Black/African American29 (12.0)35 (13.8)16 (12.9)17 (12.9)
Other20 (8.3)22 (8.7)1 (0.8)2 (1.5)
White176 (73.0)179 (70.8)99 (79.8)109 (82.6)
GCs dosage, n (%)‡§<10 mg/day119 (48.8)132 (51.2)54 (44.3)58 (43.9)
≥10 mg/day125 (51.2)126 (48.8)68 (55.7)74 (56.1)
SLEDAI-2K score, categorical, n (%)‡0–10119 (48.8)132 (51.2)36 (29.0)38 (28.8)
≥10125 (51.2)126 (48.8)88 (71.0)94 (71.2)
IFN 4-gene test status‡¶, n (%)High199 (81.6)211 (81.8)95 (77.9)103 (78.0)
Low45 (18.4)47 (18.2)27 (22.1)29 (22.0)
  • *The proteomics dataset comprised patients from TULIP-1 only.

  • †Race group was reported by the patients.

  • ‡The baseline characteristics presented here were stratification factors used for randomisation of patients at the start of the TULIP-1 and TULIP-2 trials.

  • §Oral prednisone or equivalent.

  • ¶IFNGS test status at screening.

  • GCs, glucocorticoids; IFN, interferon; n, number of patients; SLE, systemic lupus erythematosus; SLEDAI-2K, SLE Disease Activity Index 2000.